ON Semiconductor (NasdaqGS:ON) Posts 30% Price Surge Over Last Month Despite Q1 2025 Net Loss
ON Semiconductor has been actively engaging in a share buyback program, with a significant tranche completed that may have bolstered investor confidence. Despite reporting a net loss for the first quarter of 2025, alongside reduced sales figures, the company's stock price increased by 30% over the last month. This sharp rise contrasts the broader market's more modest 4% uptick, suggesting that ON's ongoing share repurchases, despite negative earnings news, may have contributed positively to investor sentiment and possibly influenced the significant share price movement within this timeframe.
You should learn about the 2 weaknesses we've spotted with ON Semiconductor.
Uncover the next big thing with financially sound penny stocks that balance risk and reward.
The recent news of ON Semiconductor's share buyback program, despite the unfavorable earnings report, has seemingly influenced investor sentiment positively, leading to a notable rise in its share price. This upward movement contrasts with the company's performance over the past year, where it underperformed against the US Semiconductor industry's 18.5% return. Over a five-year period, however, ON Semiconductor's total return, including share price growth and dividends, was 195.67%, highlighting its stronger long-term performance.
The current narrative points to ON Semiconductor's efforts to revitalize its growth through the Fab-Right strategy and expansion into silicon carbide technology, particularly in automotive and AI data centers. This could potentially translate into positive impacts on revenue and earnings forecasts. Analysts expect a moderate revenue growth of 4% and significant earnings growth of 33.5% annually over the next three years, indicating an optimistic outlook contingent on overcoming current challenges.
The company's share price increase to US$38.51 still sits below the consensus price target of US$48.23 as of today, reflecting a 20.1% discount to the analysts' fair value estimation. While the analysts have varied expectations, with targets ranging from US$33.0 to US$72.12, the divergence suggests different perspectives on how ON Semiconductor's strategies will evolve. Investors should evaluate how the company's strategic initiatives in R&D and market expansion are likely to impact its financial outcomes relative to these targets.
Review our historical performance report to gain insights into ON Semiconductor's track record.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:ON.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
ASCO25: AI test shown to aid in prostate cancer treatment planning
New research has demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga) is an androgen deprivation therapy (ADT) used in men with metastatic castration-resistant prostate cancer (mCRPC) that no longer responds to standard hormone therapy. The ArteraAI test assesses prostate needle biopsy images to provide risk stratification and prediction of the benefits of ADT for prostate cancer patients. Researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) applied the test to biopsy images from more than 1,000 men who took part in the Stampede trial (NCT00268476), coordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL and funded by Cancer Research UK. ArteraAI helped identify that 25% of men with high-risk prostate cancer from the Stampede trial who would most likely benefit from receiving abiraterone. For those patients with biomarker-positive tumours, abiraterone cut the risk of death after five years from 17% to 9%. Full details of the study will be shared during a presentation at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place from 30 May to 3 June in Chicago, Illinois. Nick James, professor of prostate and bladder cancer research at the Institute of Cancer Research and consultant clinical oncologist at the Royal Marsden NHS Foundation Trust, served as chief investigator on the STAMPEDE and is co-leader of the current research. James noted that since abiraterone comes with potential side effects that may require additional monitoring, such as potential issues with high blood pressure and liver abnormalities, knowing who is most likely to benefit is 'very valuable'. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.' Abiraterone is indicated for use on the UK National Health Service (NHS) in England for patients with advanced prostate cancer that has come back and spread to other parts of the body, but not for patients newly diagnosed with high-risk prostate cancer that has not yet spread. However, abiraterone has been available for men with this indication in Scotland and Wales for two years. The study's co-lead UCL Cancer Institute professor Gert Attard commented: 'This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over-treatment while maximising the chance of cure." "ASCO25: AI test shown to aid in prostate cancer treatment planning" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Miami Herald
30 minutes ago
- Miami Herald
China Reacts to Trump Taiwan Arms Report: ‘Red Line'
China warned the U.S. of its "first red line that cannot be crossed" after a report that President Donald Trump intends to increase arms sales to Taiwan. The Trump Administration will lift weapons sales to Taiwan to higher levels than during his first administration, Reuters reported, citing U.S. officials, to put more military pressure on Beijing. "The Taiwan question is at the core of China's core interests and the first red line that cannot be crossed in China-US relations," Lin Jian, spokesman for the Chinese foreign ministry, said at a press briefing on Friday. "China firmly opposes the US' arms sales to China's Taiwan region, urges the US to abide by the One China principle, and the three China-US joint communiqués, especially the August 17 communiqué of 1982. "Stop selling arms to Taiwan and stop creating new factors that could lead to tensions in the Taiwan Strait. China is firmly resolved in defending its national sovereignty and territorial integrity." This is a breaking news story. More to follow. Related Articles China Warns US Over Trump's 'Golden Dome'Trump and Xi Jinping May Have a Call Amid 'Stalled' Talks: Scott BessentDrinking Water Contamination Sparks Faucet RecallWill There Be a Trump Tariff Refund? 2025 NEWSWEEK DIGITAL LLC.


Associated Press
39 minutes ago
- Associated Press
DFI Retail Group Divests Shares in Robinsons Retail
HONG KONG SAR - Media OutReach Newswire - 30 May 2025 - DFI Retail Group Holdings Limited ('DFI' or the 'Group') today announces the sale of 315,309,310 common shares in Robinsons Retail Holdings, Inc. ('RRHI'), representing approximately 22.2% of RRHI's outstanding shares. This transaction reflects DFI's strategic pivot from a portfolio investor to a focused operating company, enabling the Group to divest minority positions and redeploy capital to support the growth and higher returns of subsidiary businesses. DFI first became a significant minority shareholder in RRHI in 2018 through the share-for-share swap transaction involving Rustan Supercenters, Inc. Following this divestment, the Group will review the use of the divestment proceeds to support its capital allocation strategy and long-term growth priorities which include - but not be limited to - expanding digital retail media, advancing own brand innovation, and enhancing omnichannel capabilities across its key markets. DFI remains confident in RRHI's long-term prospects and the continued success of their exclusive distribution of Meadows and Guardian brands. Scott Price, Group Chief Executive of DFI Retail Group, said, 'We would like to sincerely thank the Robinsons Retail team for their hard work, partnership, and commitment over the years. Our collaboration has been instrumental in growing our presence in the Philippines, and we look forward to continuing this strong relationship as we each focus on our strategic priorities.' 'This transaction represents a significant step in our evolution as an operating company, enabling us to redeploy capital to support growth and enhance shareholder returns across our subsidiary businesses. We will evaluate the deployment of divestment proceeds to ensure alignment with our capital allocation strategy and long-term growth ambitions.' The transaction was executed via a special block sale on the Philippine Stock Exchange, with pricing agreed upon based on prevailing market conditions and strategic considerations. Hashtag: #DFIRetailGroup The issuer is solely responsible for the content of this announcement. DFI Retail Group DFI Retail Group is a leading Asian retailer, driven by its purpose to 'Sustainably Serve Asia for Generations with Everyday Moments'. As at 31 December 2024, the Group, its associates and joint ventures operated over 10,700 outlets, of which more than 5,000 stores were operated by subsidiaries. The Group, together with associates and joint ventures, employed over 190,000 people, with over 45,000 people employed by subsidiaries. The Group had total annual revenue in 2024 of US$24.9 billion and reported revenue of US$8.9 billion. The Group is dedicated to delivering quality, value and service to Asian consumers through a compelling retail experience, supported by an extensive store network and highly efficient supply chains. The Group, including associates and joint ventures, operates a portfolio of well-known brands across six key divisions: health and beauty, convenience, food, home furnishings, restaurants and other retailing. The Group's parent company, DFI Retail Group Holdings Limited, is incorporated in Bermuda and has a primary listing in the equity shares (transition) category of the London Stock Exchange, with secondary listings in Bermuda and Singapore. The Group's businesses are managed from Hong Kong. DFI Retail Group is a member of the Jardine Matheson group.